Articles

PP42 Th17 impact on xenogeneic graft-versus-host disease

BJH - 2018, issue Abstract Book BHS, february 2018

L. Delens , G. Ehx , L. Vrancken , G. Fransolet , C. Grégoire MD, M. Hannon , S. Dubois , C. Daulne , Y. Beguin MD, PhD, F. Baron MD, PhD, S. Servais MD, PhD

Read more

PP43 Graft-versus-host disease (GVHD) of the central nervous system (CNS) after allogeneic hematopoietic cell transplantation (alloHCT): case report

BJH - 2018, issue Abstract Book BHS, february 2018

M. Pirotte , F. Forte , L. Lutteri , B. Otto , E. Willems MD, PhD, L. Belle , F. Baron MD, PhD, Y. Beguin MD, PhD, P. Maquet , O. Bodard , S. Servais MD, PhD

Read more

Multiple myeloma bone disease: from mechanisms to next generation therapy

BJH - volume 8, issue 2, march 2017

R. Heusschen PhD, J. Muller MSc, N. Withofs MD, PhD, F. Baron MD, PhD, Y. Beguin MD, PhD, J. Caers MD, PhD

SUMMARY

Multiple myeloma bone disease is a major cause of morbidity and mortality in multiple myeloma patients and persists even in patients in remission. Multiple myeloma bone disease is caused by an uncoupling of bone remodelling, with increased osteoclast activity and decreased osteoblast activity, culminating in lytic bone destruction. Bisphosphonates are the current standard-of-care but new therapies are needed. As the molecular mechanisms controlling multiple myeloma bone disease are increasingly understood, new therapeutic targets are extensively explored in the preclinical setting and initial clinical trials with novel compounds show promising results. In this review, we provide a comprehensive overview of the biology of multiple myeloma bone disease, summarise its current clinical management and discuss preclinical and clinical data on next generation therapies.

(BELG J HEMATOL 2017;8(2):66–74)

Read more

PP05 The detection rate of PET/CT after co-administration of [18F]NaF and [18F]FDG is superior to the detection rate of whole-body MRI in the diagnosis of MM lesions

BJH - volume 8, issue Abstract Book BHS, february 2017

J. Caers MD, PhD, N. Withofs MD, PhD, F. Cousin , T. Tancredi , P. Simoni , B. De Prijck MD, K. Hafraoui , C. Bonnet MD, PhD, R. Heusschen PhD, V. Alvarez-Miezentseva , R. Hustinx , Y. Beguin MD, PhD

Read more

P12 The glycan-binding galectin-1 is involved in osteoclast biology

BJH - volume 8, issue Abstract Book BHS, february 2017

J. Muller MSc, M. Binsfeld , S. Dubois , G. Carmeliet , Y. Beguin MD, PhD, R. Heusschen PhD, J. Caers MD, PhD

Read more

PP74 Limited impact of imatinib in a murine model of sclerodermatous chronic graft-versus-host disease

BJH - volume 8, issue Abstract Book BHS, february 2017

G. Fransolet , L. Belle , J. Somja MD, M. Binsfeld , P. Delvenne , P. Drion , M. Hannon , Y. Beguin MD, PhD, G. Ehx , F. Baron MD, PhD

Read more

PP71 Impact of Tofacitinib on xenogeneic graft versus host disease

BJH - volume 8, issue Abstract Book BHS, february 2017

M. Hannon , C. Grégoire MD, J. Muller MSc, G. Fransolet , L. Delens , Y. Beguin MD, PhD, G. Ehx , F. Baron MD, PhD

Read more